Maidenhead, England (ots/PRNewswire) - - New Study Results Further Support That Enbrel Effectively Clears Skin, Reduces the Prevalence of Depression and Anxiety and Improves Patients' Quality of Life Data demonstrating the significant positive impact of Enbrel (etanercept) on the quality of life of ...
Collegeville, Pennsylvania (ots/PRNewswire) - - First African Nation Plans to Phase in Routine Vaccination Program Against Pneumococcal Disease for Infants and Young Children - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that South Africa has initiated an immunization program against pneumococcal disease with PREVENAR(R) ...
Maidenhead, England (ots/PRNewswire) - - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide MAIDENHEAD, England, September 4 /PRNewswire/ -- Wyeth today announced that Cyprus and the Republic of Ireland have initiated national ...
Maidenhead, England (ots/PRNewswire) - - New Dosing Option Provides Greater Flexibility and Convenience for Patients to Effectively Control the Debilitating Symptoms of their Condition(1) The European Commission announced today a new 50 mg Enbrel(R) (etanercept) once weekly dosage regimen as an ...
Maidenhead, England (ots/PRNewswire) - - PREVENAR Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their ...
Maidenhead, England (ots/PRNewswire) - - First-in-Class Treatment set to Provide a New and Important Targeted Treatment for Distressing and near Universal Side Effect in Patients Receiving Opioids for Pain Relief as Part of Palliative Care Wyeth Pharmaceuticals, today 3rd July, announced that it ...
Maidenhead, England (ots/PRNewswire) - - Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel(R) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps Patients Return to More Normal and Productive Lives Data presented ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is ...
Istanbul, Turkey (ots/PRNewswire) - - New Studies Provide Clinical Support for More Flexible and Convenient Dosing Options for Patients New data from key clinical trials presented today at the 5th European Academy of Dermatology and Venereology (EADV) Spring Symposium in Istanbul, demonstrate that ...
Maidenhead, England (ots/PRNewswire) - - PREVENAR Shown to Reduce Invasive Pneumococcal Disease in Young Children Data presented at the 26th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Graz, Austria, provide additional evidence of the public health impact of the routine use of Prevenar* (Pneumococcal Saccharide ...
COLLEGEVILLE, Pennsylvania and TARRYTOWN, New York, April 24 (ots/PRNewswire) -- - Final Decision from European Commission Expected by Mid-2008 Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received a ...
Liverpool, England (ots/PRNewswire) - - Irrespective of Budgetary Restrictions, etanercept Dose Escalation Remains Low Suggesting etanercept Achieves Sustained Efficacy and is a Cost Effective Treatment for Rheumatoid Arthritis New pan-European data presented today at the British Society of Rheumatology's ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Wyeth Withdraws European Application Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it is withdrawing its application for an extension to the European Marketing Authorization for TYGACIL(R) (tigecycline). This extension sought approval of TYGACIL for the treatment ...
Madison, New Jersey (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use (CHMP) regarding the risk-benefit profile of desvenlafaxine as ...
Maidenhead, England (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the European Medicines Agency (EMEA) has validated the marketing authorisation application for Torisel(R) (temsirolimus) for treating relapsed and/or refractory mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL) that accounts for ...
Collegeville, Pennsylvania, November 26 (ots/PRNewswire) - - TORISEL Extends Median Overall Survival vs. Interferon-Alpha Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved TORISEL(TM) (temsirolimus) for the first-line treatment of patients ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies. This acquisition significantly increases Wyeth's already ...
Collegeville, Pennsylvania (ots/PRNewswire) - - European Committee Issues Negative Opinion on MYLOTARG(R) for Acute Myeloid Leukemia; Wyeth Plans to Appeal Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Maidenhead, England (ots/PRNewswire) - - Enhancements Provide Haemophilia B Patients with a Simpler and More Convenient Preparation Process for Recombinant Factor IX - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received approval from the European Medicines Agency (EMEA) for new enhancements for BeneFix(R) nonacog ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has assumed all marketing and distribution rights to BeneFIX(R) Coagulation Factor IX (Recombinant) in Europe. This transfer of responsibility follows the planned June 30, 2007 conclusion of a 10-year distribution rights agreement between Baxter Healthcare Corporation and Genetics Institute. ...
Collegeville, Pennsylvania (ots/PRNewswire) - - TORISEL Is Proven to Extend Overall Survival for People with Advanced Renal Cell Carcinoma - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) has approved TORISEL(TM) (temsirolimus) for ...
Vienna, Austria (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced new data that showed that, in moderate to severe plaque psoriasis patients, ENBREL(R) (etanercept) reduced the severity of nail psoriasis by more than 28 percent at 12 weeks and reduced the signs and ...
Collegeville, Pennsylvania and Tarrytown, New York (ots/PRNewswire) - - Application for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that Wyeth has ...